BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GenomeQuest, Inc. to Lead Biomarker World Congress Panel on Applying Whole Genome Sequencing to Developing Companion Diagnostics


5/3/2011 9:00:09 AM

WESTBOROUGH, Mass., May 2, 2011 /PRNewswire/ -- Richard Resnick, GenomeQuest's chief executive officer, will moderate a distinguished panel on Tuesday, May 3, 2011, at the Biomarker World Congress in Philadelphia titled "The Impact of Next Generation/Whole-Genome Sequencing on Companion Diagnostics" for pharmaceutical and biotechnology companies that are advancing to next generation sequencing and data management technologies.

The Biomarker World Congress panel will be held Tuesday from 11:45 a.m. to 12:30 p.m. (EDT) at the Lowes Philadelphia Hotel and simulcast through WebEx via the following link: https://eval.webex.com/eval/onstage/g.php?t=a&d=920931500. To access the teleconference, North American listeners can dial 1-650-429-330 or 866-469-3239 and use access code 920931500.

Panel participants:

  • Richard Wilson, Ph.D., Professor and Director, The Genome Center at Washington University School of Medicine
  • Dr. Dom Spinella, Ph.D., Executive Director Translational Medicine, Pfizer Inc.
  • Dr. Michael Nohaile, Ph.D., Global Head, Novartis Molecular Diagnostics
  • Glenn Miller, Ph.D., Vice President and Head of Personalized Healthcare & Biomarker Strategy, Portfolio & Alliances, AstraZeneca
  • Iya Khalil, Ph.D., Co-Founder and Executive Vice President, GNS Healthcare

Key questions for the panel discussion:

  • Will whole genome sequencing (WGS) companion diagnostics (CDx) be a practical/high ROI genomics investment for pharma and why or not?
  • Can WGS-CDx be transformational in drug rescue and how?
  • How will WGS-CDx affect the design and operation of clinical trials?
  • What practical steps/investments should pharma be making in this area?
  • What advances/benefits of WGS are creating these opportunities?
  • How will this affect the strategies of diagnostic companies and research labs?
  • Which therapeutic areas offer the most promise in the near-term?

Whole-genome sequencing applied to diagnostics holds great promise for health care. Of the $5 trillion spent globally on health care, about 65% of therapy decisions are based on diagnostic test results. WGS companion diagnostics, which can predict an individual's response to a drug, are expected to transform drug discovery and development and patient care.

"GenomeQuest enables pharmaceutical and biotechnology companies to develop WGS-based diagnostics as pure software an advance which adds immense precision and efficiencies to the industry," Resnick says. "Software algorithms armed with whole genome data can fully capture and assess the increasingly complex genetic factors of diseases and breakthroughs can be delivered far faster and cheaper through software updates than by producing whole new diagnostic machines and reagents."

About GenomeQuest:

GenomeQuest, the global leader in sequence data management, helps life science organizations realize the full promise of genomics. More than 160 leading health and agriculture companies, including nine of the top ten pharmaceuticals, use GenomeQuest for mission-critical work. The core technology of the company is the GQ-Enginea sequence database engine that is purpose-built for storing, managing, and analyzing sequence data at whole- and multi-genome scale.

Learn more atwww.genomequest.com.

SOURCE Waggener Edstrom Worldwide



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES